Delayed treatment with doxycycline has limited effect on anthrax infection in BLK57/B6 mice

J Kalns, J Morris, J Eggers, J Kiel - Biochemical and biophysical research …, 2002 - Elsevier
J Kalns, J Morris, J Eggers, J Kiel
Biochemical and biophysical research communications, 2002Elsevier
Blk57/B6 mice were infected with LD90 dose of Sterne strain anthrax spores subcutaneously
and then treated with doxycycline. Doxycycline at a dose of 1.5 mg/kg, by intra-peritoneal
injection, protected mice from death when given at the same time as spores. When
doxycycline administration was delayed 4h survival is 90%. Delay of 24h increased survival
time but had no impact on eventual mortality. When doxycycline was delayed 48h, mortality
and time to death were comparable to sham injection. Peritoneal macrophages harvested …
Blk57/B6 mice were infected with LD90 dose of Sterne strain anthrax spores subcutaneously and then treated with doxycycline. Doxycycline at a dose of 1.5mg/kg, by intra-peritoneal injection, protected mice from death when given at the same time as spores. When doxycycline administration was delayed 4h survival is 90%. Delay of 24h increased survival time but had no impact on eventual mortality. When doxycycline was delayed 48h, mortality and time to death were comparable to sham injection. Peritoneal macrophages harvested from Blk57/B6 mice were examined for response to anthrax lethal toxin and are shown to be deficient in their ability to produce TNF-α and have increased expression of IL-6 compared to RAW 264.7 murine macrophage cell line. These findings suggest that antibiotic therapy has limited effects following lethal anthrax spore challenge, even when the host is of a phenotype that does not produce TNF-α in response to anthrax lethal toxin exposure.
Elsevier